BlackRock, Inc. 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-04 3:45 pm Purchase |
2024-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BlackRock Inc. BLK |
3,840,165 6.300% |
1,468,185 (+61.90%) |
Filing |
| 2024-02-14 11:22 am Sale |
2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BlackRock Inc. BLK |
2,371,980 4.700% |
-1,226,556 (-34.08%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BlackRock Inc. BLK |
3,598,536 7.400% |
2,006,738 (+126.07%) |
Filing |
| 2022-02-09 5:22 pm Sale |
2022-01-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BlackRock Inc. BLK |
1,591,798 3.400% |
-761,966 (-32.37%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BlackRock Inc. BLK |
2,353,764 5.100% |
2,353,764 (New Position) |
Filing |